UK – NICE rejects Genzyme’s Caprelsa for medullary thyroid cancer

NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.

According to the Institute, while Caprelsa (vandetanib) may delay the disease getting worse compared with best supportive care, “but the benefit is uncertain”.

Also, it says evidence about whether the drug increases the overall survival is “unreliable”.

Clinical experts felt Caprelsa is likely to be as effective as Ipsen’s Cometriq (cabozantinib), the only other NICE recommended systemic treatment option for unresectable, locally advanced or MTC, but that cost-effectiveness estimates compared with either cabozantinib or best supportive care “are much higher than what NICE normally considers an acceptable use of NHS resources”…